Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluocinonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 0.74 |
| ▸ | LMNA | P02545 | 7/20 | 0.74 |
| ▸ | PGR | P06401 | 7/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.74 |
| ▸ | AR | P10275 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluocinolone Acetonide SCHEMBL8450831 | 0.95 | NR3C1 (0.77) | NR3C1LMNAPGRHIF1AAR | |
| Amcinonide SCHEMBL22684943 | 0.91 | NR3C1 (0.64) | NR3C1LMNAPGRHIF1AAR | |
| Difluprednate SCHEMBL4959751 | 0.90 | LMNA (0.66) | NR3C1LMNAPGRHIF1AAR | |
| Amcinonide SCHEMBL1832816 | 0.89 | LMNA (0.77) | NR3C1LMNAPGRHIF1AAR | |
| Fluocinonide SCHEMBL28089918 | 0.89 | NR3C1 (0.94) | NR3C1LMNAPGRHIF1AAR | |
| Fluocinonide SCHEMBL8425065 | 0.87 | HIF1A (0.64) | NR3C1LMNAPGRHIF1AAR | |
| Fluocinolone Acetonide SCHEMBL2251974 | 0.86 | NR3C1 (0.82) | NR3C1LMNAPGRHIF1AAR | |
| Fluocinonide SCHEMBL13568069 | 0.86 | HIF1A (1.00) | NR3C1LMNAPGRHIF1AAR | |
| Fluocinonide SCHEMBL9338347 | 0.86 | HIF1A (1.00) | NR3C1LMNAPGRHIF1AAR | |
| Fluocinonide SCHEMBL2800723 | 0.86 | HIF1A (1.00) | NR3C1LMNAPGRHIF1AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016015094-A1 | TOPICAL COMPOSITION | ACRUX DDS PTY LTD (AU) | 2016-02-04 | — | — | WO | claimed |
| US-20070287688-A1 | Pharmaceutical Compositions for Topical Application | MACRO CHEM CORPORATION | 2007-12-13 | — | — | US | claimed |
| EP-1648364-A2 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION | MacroChem Corporation (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2005007100-A2 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION | MACROCHEM CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
| US-11975121-B2 | Protein biomaterials and biocoacervates and methods of making and using thereof | PETVIVO HOLDINGS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-11975101-B2 | Compositions and methods for the treatment and prophylaxis of surgical site infections | POLYPID LTD. (IL) | 2024-05-07 | — | — | US | disclosed |
| WO-2024030437-A1 | FUNCTIONALIZED AND CROSSLINKED POLYMER METHODS AND COMPOSITIONS | PMIDG, LLC (US) | 2024-02-08 | — | — | WO | disclosed |
| US-11890371-B2 | Biocompatible protein-based particles and methods thereof | PETVIVO HOLDINGS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20240033283-A1 | FUNCTIONALIZED AND CROSSLINKED POLYMERS | POLY-MED, INC. | 2024-02-01 | — | — | US | disclosed |
| US-20230312764-A1 | FUNCTIONALIZED AND CROSSLINKED POLYMERS | PMIDG LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-11752086-B2 | Topical formulations and methods | MYOCEPT INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220395462-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PROPHYLAXIS OF SURGICAL SITE INFECTIONS | KREOS CAPITAL VI (EXPERT FUND) LP (JE) | 2022-12-15 | — | — | US | disclosed |
| EP-1105110-A1 | SPRAY ON BANDAGE AND DRUG DELIVERY SYSTEM | 3M Innovative Properties Company (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2001039756-A1 | PATCH THERAPEUTIC AGENT DELIVERY DEVICE HAVING TEXTURIZED BACKING | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001039755-A1 | THERAPEUTIC AGENT DELIVERY DEVICE INCORPORATING REFLECTIVE OPTICAL FILM | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001037890-A1 | A PROPELLANT FREE SPRAY-ON SKIN PATCH COMPOSITION FOR IMPROVING WOUND HEALING AND FOR DRUG ADMINISTRATION | EVER POWER HOLDING INC (VG) | 2001-05-31 | — | — | WO | disclosed |
| WO-2000010540-A1 | SPRAY ON BANDAGE AND DRUG DELIVERY SYSTEM | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-03-02 | — | — | WO | disclosed |
| EP-0901368-A4 | DERMAL PENETRATION ENHANCERS AND DRUG DELIVERY SYSTEMS INVOLVING SAME | UNIV MONASH (AU) | 2000-01-26 | — | — | EP | disclosed |
| EP-0901368-A1 | DERMAL PENETRATION ENHANCERS AND DRUG DELIVERY SYSTEMS INVOLVING SAME | MONASH UNIVERSITY (AU) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997029735-A1 | DERMAL PENETRATION ENHANCERS AND DRUG DELIVERY SYSTEMS INVOLVING SAME | MONASH UNIVERSITY (AU) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287688-A1 | Pharmaceutical Compositions for Topical Application | CYP8B1, NR1H3, NR1H2 | NR3C1 615/4885LMNA 1726/4885PGR 449/4885 |
| US-20240033283-A1 | FUNCTIONALIZED AND CROSSLINKED POLYMERS | VCL, PARN, PARG | NR3C1 4722/4885LMNA 1135/4885PGR 1107/4885 |
| US-11752086-B2 | Topical formulations and methods | KRT18, ANXA3, VIP | NR3C1 3044/4885LMNA 2274/4885PGR 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.